Table 4.
Pharmacokinetic and pharmacodynamic parameters of linezolid using concentrations in plasma, VDBS, and DBS
| Patient | Dose (mg)a | MIC (mg/liter) | AUC0–12 (mg · h/liter) in: |
AUC0–24/MIC in: |
||||
|---|---|---|---|---|---|---|---|---|
| Plasma | VDBSb | DBSb | Plasma | VDBSb | DBSb | |||
| 1 | 300 | 0.5 | 50.1 | 46.7 | 51.5 | 201 | 187 | 206 |
| 2 | 300 | 0.25 | 50.9 | 54.2 | 50.7 | 407 | 433 | 405 |
| 3 | 600 | 0.5 | 121.6 | 118.1 | 112.1 | 486 | 472 | 449 |
| 4 | 600 | <0.125 | 127.6 | 130.9 | 114.2 | >2,042 | >2,094 | >1,827 |
| 5 | 600 | 0.5 | 126.9 | 132.0 | 140.2 | 508 | 528 | 561 |
| 6 | 600 | 0.5 | 66.6 | 69.4 | 64.2 | 266 | 278 | 257 |
| 7 | 300 | 0.5 | 58.9 | 46.1 | 42.4 | 236 | 184 | 170 |
| 8 | 600 | 0.25 | 174.7 | 183.1 | 189.6 | 1,398 | 1,465 | 1,517 |
a
Twice daily.
b
Relative AUC0–12 and AUC0–24/MIC calculated using conversion factors (i.e., 1.20 for DBS and 1.36 for VDBS).